Document is current

Article History

Received: 23 October 2023

Accepted: 13 September 2024

First Online: 25 October 2024

Competing interests

: P.Ad. declares grant funding paid to her institution from NIHR, MRC and Colt Foundation, funding to Institution and to cover expenses as Chair of NIHR Public Health Research Funding Committee, Deputy Director of NIHR School for Public Health Research, funding to cover expense as Member of Wellcome Trust Early Career Advisory Group in Population and Public Health, Output Assessor for Panel A, subpanel 2 in 2021 Research Excellence Framework, and unfunded contributions as Chair for several NIHR funded TSCs, Member of the MRC funded Natural Experiments Evaluations Project Oversight Group, Member of Obesity Health Alliance Independent Obesity Strategy Working Group, Member of NIHR palliative and End of Life Care Research Partnerships call Panel, NIHR/UKRI Long COVID funding call Panel, NIHR COVID-19 Recovery and Learning Funding Committee; J.C-De-S. declares grant funding to his institution from AstraZeneca and GSK, advisory board and consulting fees paid to himself from Boheringer Ingelheim, GSK, AstraZeneca, Bial, Medinfar, Payment for lectures from GSK, AstraZeneca and Sanofi Pasteur, support for attending meetings from Mundipharma and Mylan, leadership role for International Primary Care Respiratory Group (IPCRG); A Farley declares grant funding paid to her institution from NIHR GHR for the present manuscript, grant funding from NIHR HTA, NIHR EME, MRC and Ethicon (Johnson and Johnson) for other work, membership on DMEC for NIHR funded e-cigarette trial (no honorarium), leadership role for International Primary Care Respiratory Group (IPCRG) and as expert funding panel member for Cancer Research UK personal funding for; K.J. declares grant funding paid to her institution from NIHR and MRC, participant in Data Safety Monitoring Board or advisory board for NIHR funded studies (no honorarium), Sub-committee chair of NIHR Programme Grants for Applied Health Research (payments to institution); R.J. declares grant funding to her institution from NIHR, membership of Boehringer Ingelheim Primary Care Advisory Board, unfunded leadership role for International Primary Care Respiratory Group (IPCRG) – research sub-committee, membership of NIHR Global Health Group panel and RfPB COPD Highlight panel; S.J. declares grant funding to her institution from NIHR GHR for present manuscript and unfunded membership of the HTA Funding Committee Policy Group (formerly CSG) and the HTA Clinical Evaluation and Trials Committee; S.M.M. declares leadership or fiduciary do GEPRAPS (Respiratory Group of Study and Research in Primary Care) of Center for Public Health Studies (CESCO) at the University Center of the ABC Medical School, São Paulo, Brazil, IPCRG (Internacional Primary Care Respiratory Group); A Sitch declares grant funding to her institution from NIHR GHR for present manuscript, NIHR Birmingham BRC and AstraZeneca; A Turner declares grant funding to her institution from NIHR GHR for present manuscript, grant funding from AstraZeneca and Chiesi for other work, payment of honoraria from GSK and Boehringer, support for attending meetings and/or travel from AstraZeneca and Chiesi; S.W. declares grants from the University of Birmingham paid to her institution, her institution has received conference sponsorship and independent educational grants from Pfizer Global Medical Grants, AstraZeneca, GSK, Boehringer Ingelheim, Vitalograph, Caire Diagnostics and Thorasys; R.A., K.K.C., C.Chi., B.C., A.D., A.E., N.G., T.M., M.M., K.S., S.R. declare grant funding to their institution from NIHR GHR for current manuscript; V.B.N., E.R. have no financial or non-financial conflicts to declare.